> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bioptimus hits $76m funding milestone for AI foundation model launch
- URL: https://med-techinsights.com/bioptimus-hits-76m-funding-milestone-for-ai-foundation-model-launch/
- Published: 2025-04-02T08:56:01.000Z
- Updated: 2026-10-22T07:53:07.000Z
- Description: Bioptimus, an AI foundation model company, has announced that it has reached a significant funding milestone of 76 million USD. This total includes a 41 million USD cash injection, led by Cathay Innovation with participation from prominent investors, including Sofinnova Partners, Bpifrance through i
- Author: Oliver Johnson
- Tags: Digital Health & AI, News, Artificial Intelligence

[**Bioptimus**](https://www.bioptimus.com/?ref=med-techinsights.com), an AI foundation model company, has announced that it has reached a significant funding milestone of 76 million USD. This total includes a 41 million USD cash injection, led by Cathay Innovation with participation from prominent investors, including Sofinnova Partners, Bpifrance through its Large Venture Fund, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Pomifer Capital, Sunrise, and angel entrepreneurs Emmanuel Cassimatis and Thomas Wolf.

The funding will accelerate Bioptimus’s mission to build the world’s first universal AI foundation model for biology, aimed at revolutionising research and innovation across the medical, biotech, cosmetic industries, and beyond.

This year, the company released its first model, H-Optimus-0, what it says is the world’s largest foundation model for pathology.

Bioptimus claims that H-Optimus-0 has already outperformed all other pathology models in independent benchmarks, including assessments conducted by Harvard Medical School’s HEST program and the University of Leeds. These studies highlighted the model’s ability to predict gene expression from morphology and to subtype ovarian cancer with exceptional accuracy.

Bioptimus says it is redefining how we approach biological research by addressing a longstanding issue: the siloed nature of biological understanding. Historically, research has focused on isolated biological components, such as DNA, proteins, cells or tissues.

Existing AI foundation models operate within these silos, limiting their potential impact. Bioptimus’s revolutionary approach integrates data across multiple scales (molecules, cells, tissues, organisms) and modalities (imaging, genetics, etc), enabling a holistic view of biology as it exists in reality.

Jean-Philippe Vert, co-founder and CEO of Bioptimus stated: “What we are building is not just a technological breakthrough; it’s a transformative tool for understanding biology in its full complexity. By learning how biology works directly from raw data across scales, from molecules to whole organisms, our model will empower researchers in the pharmaceutical industry to simulate complex biology, predict disease outcomes and response to treatment, and design therapies with unprecedented precision. Beyond pharmaceuticals, this model will unlock limitless possibilities across many other industries, driving biological discoveries in ways we are only beginning to imagine. Essentially, it’s like the GPT of biology—but instead of generating text, we’re simulating biology.”

The funding will enable Bioptimus to enhance its multi-modal AI platform, integrating even more diverse data sources and therapeutic areas, forge strategic partnerships with pharmaceutical and biotech companies and expand critical datasets to further refine and validate its models.

Jacky Abitbol, Partner at Cathay Innovation said: “Bioptimus is at the forefront of transforming biological research, leveraging cutting-edge AI to break down silos and unlock the full complexity of biology. By integrating data across multiple scales and modalities, Bioptimus is paving the way for groundbreaking innovations across industries, from pharmaceuticals to biotechnology and beyond. We are delighted to see that since our initial investment a year ago, Bioptimus has succeeded in structuring a world-class team, while achieving key milestones in its development, notably with the launch of its AI foundation model for pathology in July, the largest in the world.”